Skip to content
TrialScanner

NCT03796962

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Phase 2Active, not recruitingXENELead

Registry record

Lead sponsor
Xenon Pharmaceuticals Inc.
Conditions
Focal Epilepsy
Primary completion
Sep 2, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03796962 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.